rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Sharon Tetlow

Director

Company insider

Files Form 4 as: Director, Structure Therapeutics; Director, DICE Therapeutics; Director, Gyre Therapeutics; Acting CFO & Treasurer, Ocera Therapeutics; SVP & CFO, Cell Genesys.

Every Form 4 they filed

In numbers

Trades disclosed
34
Buys
1
Sells
0
Bought
$17K
Sold
$0
Companies
5
Companies where not an officer
3
First trade
7 Feb 2006
Last trade
17 Jun 2026
Last filed
18 Jun 2026

Companies traded

Where they are an officer
Ocera TherapeuticsOfficer · last 11 Jul 20141 buy · 0 sells
Cell GenesysOfficer · last 14 Oct 20090 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
GPCR Structure TherapeuticsDirector · Biotechnology · last 17 Jun 20260 buys · 0 sells
DICE TherapeuticsDirector · last 9 Aug 20230 buys · 0 sells
GYRE Gyre TherapeuticsDirector · Biotechnology · last 9 Jun 20210 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
17 Jun 2026filed 18 Jun 2026GPCR Structure Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—39,453 at $0.00filing
17 Jun 2026filed 18 Jun 2026GPCR Structure Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—39,453 at $0.00filing
23 Jun 2025filed 25 Jun 2025GPCR Structure Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—51,804 at $0.00filing
25 Jun 2024filed 27 Jun 2024GPCR Structure Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—37,500 at $0.00filing
9 Aug 2023filed 9 Aug 2023DICE Therapeuticsoption or derivativeSEC FORM 4 Code D—12,096filing
9 Aug 2023filed 9 Aug 2023DICE Therapeuticsoption or derivativeSEC FORM 4 Code D—8,261filing
9 Aug 2023filed 9 Aug 2023DICE Therapeuticsoption or derivativeSEC FORM 4 Code D—13,800filing
9 Aug 2023filed 9 Aug 2023DICE Therapeuticsoption or derivativeSEC FORM 4 Code D—21,250filing
9 Aug 2023filed 9 Aug 2023DICE TherapeuticsSEC FORM 4 Code D—49,841filing
7 Jun 2022filed 8 Jun 2022DICE Therapeuticsoption or derivativeSEC FORM 4 Code A—21,250 at $0.00filing
14 Sep 2021filed 16 Sep 2021DICE Therapeuticsoption or derivativeSEC FORM 4 Code A—12,096 at $0.00filing
14 Sep 2021filed 16 Sep 2021DICE Therapeuticsoption or derivativeSEC FORM 4 Code A—8,261 at $0.00filing
14 Sep 2021filed 16 Sep 2021DICE Therapeuticsoption or derivativeSEC FORM 4 Code A—8,200 at $0.00filing
14 Sep 2021filed 16 Sep 2021DICE Therapeuticsoption or derivativeSEC FORM 4 Code A—5,600 at $0.00filing
9 Jun 2021filed 2 Jul 2021GYRE Gyre Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—14,000 at $0.00filing
1 Jul 2020filed 2 Jul 2020GYRE Gyre TherapeuticsBiotechnologySEC FORM 4 Code A—1,703 at $0.00filing
11 Jun 2020filed 12 Jun 2020GYRE Gyre Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—5,000 at $0.00filing
1 Apr 2020filed 3 Apr 2020GYRE Gyre TherapeuticsBiotechnologySEC FORM 4 Code A—1,932 at $0.00filing
15 Jan 2020filed 17 Jan 2020GYRE Gyre Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
11 Jul 2014filed 15 Jul 2014Ocera TherapeuticsSEC FORM 4 Bought$17K3,000 at $5.83filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed1

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.